Table 1. Clinical features and PLOD2 protein expression in HCC patients.
| Characteristics | N | PLOD2 expression |
p | |
|---|---|---|---|---|
| High | Low | |||
| Sex | 0.750 | |||
| Male | 94 | 46 (48.94%) | 48 (51.06%) | |
| Female | 15 | 8 (53.33%) | 7 (46.67%) | |
| Age in years | 0.640 | |||
| >50 | 65 | 31 (47.69%) | 34 (52.31%) | |
| ≤50 | 44 | 23 (52.27%) | 21 (47.73%) | |
| BCLC stage | 0.030 | |||
| I | 86 | 38 (44.19%) | 48 (55.81%) | |
| II–III | 23 | 16 (69.57%) | 7 (30.43%) | |
| Histologic grade | <0.001 | |||
| I–II | 57 | 15 (26.32%) | 42 (73.68%) | |
| III–IV | 52 | 39 (75.00%) | 13 (25.00%) | |
| AFP in µg/L | 0.640 | |||
| ≥400 | 46 | 24 (52.17%) | 22 (47.83%) | |
| <400 | 63 | 30 (47.62%) | 33 (52.38%) | |
| Vascular invasion | 0.823 | |||
| Yes | 17 | 8 (47.06%) | 9 (52.94%) | |
| No | 92 | 46 (50.00%) | 46 (50.00%) | |
| Tumor size in cm | 0.001 | |||
| ≤5 | 54 | 20 (37.04%) | 34 (62.96%) | |
| >5 | 55 | 34 (61.82%) | 21 (38.18%) | |
| Tumor number | 0.180 | |||
| Solitary | 94 | 49 (52.13%) | 45 (47.87%) | |
| Multiple | 15 | 5 (33.33%) | 10 (66.67%) | |
| HBsAg | 0.540 | |||
| Negative | 14 | 8 (57.14%) | 6 (42.86%) | |
| Positive | 95 | 46 (48.42%) | 49 (51.58%) | |
| MVI | 0.730 | |||
| Yes | 36 | 17 (47.22%) | 19 (52.78%) | |
| No | 73 | 37 (50.68%) | 36 (49.32%) | |
| Cirrhosis | 0.630 | |||
| Yes | 79 | 38 (48.10%) | 41 (51.90%) | |
| No | 30 | 16 (53.33%) | 14 (46.67%) | |
| Tumor encapsulation | 0.490 | |||
| Complete | 33 | 18 (54.55%) | 15 (45.45%) | |
| None | 76 | 36 (47.37%) | 40 (52.63%) | |
AFP, α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBsAg, hepatitis B surface antigen; MVI, microvascular invasion; PLOD2, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2. p<0.05 was considered statistically significant.